Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–10 of 10 results
Advanced filters: Author: Corinne Faivre-Finn Clear advanced filters

  • Patients with unresectable stage III non-small-cell lung cancer without EGFR or ALK mutations typically receive the PACIFIC regimen — concurrent chemoradiotherapy (cCRT) followed by consolidation with durvalumab — whereas those with EGFR-mutant disease typically receive cCRT followed by an EGFR inhibitor. Nonetheless, a subset of patients within this heterogeneous group might be able to completely avoid consolidation therapy, whereas others are unable to tolerate cCRT. In this Review, the authors describe the standard-of-care approach in this setting, followed by discussions of treatment optimization for specific subgroups, as well as important future research questions.

    • Jordi Remon
    • Antonin Levy
    • Maurice Pérol
    Reviews
    Nature Reviews Clinical Oncology
    P: 1-18

  • Imaging biomarkers (IBs) are used extensively in drug development and cancer research, but important differences exist between IBs and biospecimen-derived biomarkers. A tailored 'roadmap' is required for the development of new IBs to be used either in clinical research or for decision-making in healthcare. In this Consensus statement, a group of experts assembled by CRUK and the EORTC present 14 key recommendations for accelerating the clinical translation of IBs.

    • James P. B. O'Connor
    • Eric O. Aboagye
    • John C. Waterton
    ReviewsOpen Access
    Nature Reviews Clinical Oncology
    Volume: 14, P: 169-186

  • Non-small-cell lung cancer accounts for ~85% of lung cancers. In this Primer, Hendriks et al. summarize current knowledge and research on this malignancy, discussing its epidemiology, mechanisms, diagnosis and management, as well as quality of life and future research directions.

    • Lizza E. L. Hendriks
    • Jordi Remon
    • Martin Reck
    Reviews
    Nature Reviews Disease Primers
    Volume: 10, P: 1-22

  • Small-cell lung cancer is a rapidly proliferating cancer with a poor prognosis and is strongly associated with exposure to tobacco carcinogens. This Primer describes the epidemiology, pathogenesis and diagnosis of the disease as well as the current management approaches and new therapies that might improve outcomes.

    • Charles M. Rudin
    • Elisabeth Brambilla
    • Julien Sage
    Reviews
    Nature Reviews Disease Primers
    Volume: 7, P: 1-20

  • The DECIDE-AI checklist, resulting from a multi-stakeholder group of experts in a Delphi process and following the EQUATOR Network’s recommendations, includes key items that should be reported in early-stage clinical studies of AI-based decision support systems, to ensure a responsible and transparent deployment of AI systems in healthcare.

    • Baptiste Vasey
    • Myura Nagendran
    • Zane B. Perkins
    Reviews
    Nature Medicine
    Volume: 28, P: 924-933